Nivolumab immunotherapy safe, feasible during chemoradiation for adv. head and neck cancer – Medical Xpress
Medical Xpress |
Nivolumab immunotherapy safe, feasible during chemoradiation for adv. head and neck cancer
Medical Xpress Analysis of a clinical trial, RTOG Foundation 3504, finds that nivolumab immunotherapy can be administered safely in conjunction with radiation therapy and chemotherapy for patients with newly diagnosed local-regionally advanced head and neck cancers … |
